Tag Archives: DreaMed

Viatris’ Semglee Preferred on Express Scripts NPF; DreaMed’s Advisor Pro Launched in Leading Children’s Hospital; MiniMed 780G & Guardian 3 TIR In Pediatrics Comparable to Adults; Abbott and Roche Q3 ’21 Earnings Updates; vTv Therapeutics Hires New President and CEO; Adhera Adds Target Indications for MLR-1023

A series of cardiometabolic-related news items have been observed from Viatris, DreaMed, Medtronic, Abbott, Roche, vTv Therapeutics, and Adhera Therapeutics. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Register

Already a member? Log in here

Medtronic Expands 630G/670G Pump Recall; Xeris Completes Acquisition of Strongbridge; DreaMed FDA Clearance for AI-based Clinical Decision Support System for T2DM; Know Labs Bio-RFID Readings Comparable to FDA-Cleared Devices

A series of cardiometabolic-related news items have been observed: Medtronic recalled 600 series insulin pumps (view FDA website); Xeris announced the closing of its acquisition of Strongbridge BioPharma; DreaMed announced FDA clearance of its AI-based clinical decision support system, called Advisor Pro, for patients with T2DM; Know Labs published a report that shows the accuracy of its non-invasive Bio-RFID technology blood glucose sensor is comparable to FDA-cleared devices (press release; view report). Below, FENIX provides further highlights and insights for the respective news items. Medtronic expands 630G/670G pump recall Medtronic recently recalled an expanded set of its 600 series insulin pumps (630G and 670G)……

This content is for Read Less members only.
Register

Already a member? Log in here

DreaMed Partners with Four Additional US Health Clinics

DreaMed Diabetes announced it has partnered with four US clinics to integrate DreaMed’s Advisor Pro software into the clinics’ protocols. For context, the Advisor Pro software uses cloud-based technology and AI to perform data analyses from CGM, insulin pumps, SMBG, and event data to suggest insulin treatment recommendations. Below, FENIX provides thoughts on the partnerships in the context of COVID-19 and the acceleration toward digital health management.

This content is for Read Less members only.
Register

Already a member? Log in here

New Medtronic Professional CGM; One Drop/Bayer Partnership; EASD 2019 Key Press Releases (Sept 17)

On the second day of EASD, 7 key press releases and one new clinical trial were observed across diabetes drugs and devices. Below FENIX provides insights and context from each respective announcement.

This content is for Read Less members only.
Register

Already a member? Log in here

Thoughts on Glooko+DreaMed Data Services Franchise to Compete with Medtronic’s CareLink

The DreaMed FDA approval for its Advisor Pro algorithm now empowers Glooko to compete with Medtronic’s CareLink across the patient and provider customer segments. Below, FENIX provides insight into Glooko’s enhanced position to compete with Medtronic’s CareLink in diabetes decision support services.

This content is for Read Less members only.
Register

Already a member? Log in here